WHO ICTRP trial
Study of absorption and elimination rate of Empagliflozin tablets 10 mg in…
IRCT20200407046981N38 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200407046981N38 |
|---|---|
| Public title | Study of absorption and elimination rate of Empagliflozin tablets 10 mg in comparison with Empagliflozin brand tablets (Jardiance®). |
| Scientific title | Comparative bioequivalence study of the Empagliflozin 10 mg Tablets manufactured by Zist Arvand Pharmed Pharmaceutical Company |
| Primary sponsor | Zist Arvand Pharmed Pharmaceutical Company |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | Bioequivalence study. |
| Interventions | Intervention 1: Intervention group 1: In this group, volunteers are given a single oral dose of Empagliflozin tablet 10 mg produced by Zist Arvand Pharmed Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of… |
| Registration date | Aug 2, 2022 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: